Background Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with
platinum chemotherapy was the standard first-line chemotherapeutic regimen until the …

Prognostic features in advanced perihilar cholangiocarcinoma (pCCA) patients who
received first-line hepatic arterial infusion chemotherapy (HAIC) are unknown. The purpose …

Background Refractoriness to surgical resection and chemotherapy makes intrahepatic
cholangiocarcinoma (ICC) a fatal cancer of the digestive system with high mortality and poor …

Background Biliary tract cancer (BTC) is an aggressive biliary tract cancer, arising from the
bile ducts and gallbladder, with a poor prognosis. The TOPAZ-1 trial of durvalumab plus first …

Background Biliary tract cancers (BTCs), a heterogeneous group of cancers arising from the
biliary tract, account for∼ 15% of primary liver cancers. Patients are often diagnosed with …

Gallbladder adenocarcinoma has a high mortality rate, with approximately 1.7% cancer-
related deaths worldwide. Cancer-associated thrombosis (CAT), including deep vein …

Background and Aims Biliary tract cancer (BTC) is a rare, lethal, heterogeneous group of
cancers often diagnosed at an advanced stage. While gemcitabine plus cisplatin is the …

Simple Summary Biliary tract cancer (BTC) carries a poor prognosis. Most patients with BTC
will require 'systemic'therapy, treating cancer throughout the body to control the disease and …

Aim: Biliary tract cancers are aggressive, with poor prognosis. This study describes clinical
characteristics, treatment patterns and healthcare resource utilization in patients with …

Phase 3 trials have established standard first-line (1L) and 2L systemic therapy options for
patients with advanced biliary cancer (ABC). However, a standard 3L treatment remains …